CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 249 enrolled
Drug / intervention
Duloxetine hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00960986
NCT00960986Phase 4Completed
CompareCT.gov

A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder

Eli Lilly and Company·interventional·Posted Aug 18, 2009·Updated Dec 31, 2014

In Brief

A Phase 4 clinical trial evaluating Duloxetine hydrochloride for Major Depressive Disorder (MDD). Completed, enrolled 249 participants across 7 sites.

Detailed Summary

The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with major depressive disorder (MDD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder (MDD)
CountriesSouth Korea
CollaboratorsBoehringer Ingelheim

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 18, 2009
Enrollment StartAug 1, 2009
Primary CompletionFeb 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.9 years ago

Interventions

Duloxetine hydrochloridedrug

po, QD